Zenas BioPharma’s (ZBIO) “Buy” Rating Reiterated at HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Wednesday, Marketbeat Ratings reports. They presently have a $44.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 63.14% from the stock’s current price.

Several other equities analysts have also issued reports on the company. Guggenheim reaffirmed a “buy” rating and set a $55.00 price target on shares of Zenas BioPharma in a research note on Friday, August 14th. Wedbush reissued an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a report on Friday, August 14th. Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Zenas BioPharma Trading Up 0.8%

ZBIO stock traded up $0.21 during trading on Wednesday, hitting $26.97. The company had a trading volume of 623,232 shares, compared to its average volume of 818,694. The firm has a 50-day moving average price of $31.47 and a 200-day moving average price of $25.08. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -3.00 and a beta of -1.04.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $15.00 million. As a group, analysts predict that Zenas BioPharma will post -5.81 earnings per share for the current year.

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new position in shares of Zenas BioPharma during the 2nd quarter worth about $49,000. ProShare Advisors LLC acquired a new stake in shares of Zenas BioPharma in the 4th quarter valued at approximately $211,000. Jupiter Topco LLC bought a new position in Zenas BioPharma during the 2nd quarter worth approximately $201,000. The Manufacturers Life Insurance Company acquired a new position in Zenas BioPharma during the second quarter valued at approximately $204,000. Finally, Sei Investments Co. acquired a new position in Zenas BioPharma during the first quarter valued at approximately $242,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.